Your browser is no longer supported. Please, upgrade your browser.
Kiromic BioPharma, Inc.
Index- P/E- EPS (ttm)- Insider Own62.96% Shs Outstand7.35M Perf Week-4.42%
Market Cap25.44M Forward P/E- EPS next Y- Insider Trans0.06% Shs Float3.02M Perf Month20.56%
Income- PEG- EPS next Q- Inst Own4.86% Short Float1.09% Perf Quarter-59.77%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.10 Perf Half Y-65.47%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.64 - 18.50 Perf YTD-59.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.03% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low32.95% ATR0.30
Employees19 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)51.00 Volatility6.82% 9.43%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.39 Prev Close3.46
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume332.99K Price3.51
Recom- SMA203.95% SMA505.42% SMA200-53.29% Volume40,614 Change1.45%
Sep-13-21 09:32AM  
Aug-13-21 03:32PM  
Jul-29-21 02:44PM  
Jul-28-21 08:49PM  
Jul-26-21 08:16PM  
Jul-23-21 11:00AM  
Jul-21-21 08:23PM  
Jul-19-21 11:15AM  
Jul-16-21 02:53PM  
Jul-02-21 04:23PM  
Jun-29-21 06:59PM  
Jun-28-21 07:01AM  
Jun-17-21 07:49AM  
Jun-15-21 09:07PM  
Jun-13-21 01:06PM  
Jun-07-21 08:07AM  
May-24-21 07:55AM  
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chiriva Internati MaurizioCHIEF EXECUTIVE OFFICERSep 09Buy3.702,80010,3571,378,072Sep 10 11:47 AM